The German company Stada Group, which is engaged in the production of medicines and consumer medical products, buys the pharmaceutical business of the Ukrainian company Biofarma.
According to the Stada website, the group acquires production facilities in the city of Bila Tserkva, Kiev region.
The company notes that the deal will be closed in December 2019. At the same time, Stada emphasized that this is one of the group’s largest investments in the Ukrainian pharmaceutical sector.
“We see great potential in the Ukrainian market. Thanks to this acquisition, we will become an important player in the Ukrainian pharmaceutical market with a strong local manufacturing presence,” said Peter Goldschmidt, CEO of Stada.
The newly appointed CEO Boris Labensky will lead Stada's Ukrainian business. About 300 people will be subordinate to him.
Konstantin Efimenko, Managing Partner of Biopharma, emphasized that together with his partner Vasily Khmelnitsky and financial investors, he will focus on developing the company's plasma processing business.
The Biopharma group of companies includes Biofarma Invest LLC, Biofarma Plazma Invest LLC, Biofarma Plasma LLC, and FZ Biofarma LLC 2. The company annually produces about 200 thousand packages of drugs.